277 related articles for article (PubMed ID: 10629754)
1. Quantitative autoradiography of [3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.
García-Jiménez A; Cowburn RF; Ohm TG; Bogdanovic N; Winblad B; Fastbom J
Brain Res; 1999 Dec; 850(1-2):104-17. PubMed ID: 10629754
[TBL] [Abstract][Full Text] [Related]
2. A quantitative autoradiographic study of [3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.
Bonkale WL; Cowburn RF; Ohm TG; Bogdanovic N; Fastbom J
Brain Res; 1999 Feb; 818(2):383-96. PubMed ID: 10082824
[TBL] [Abstract][Full Text] [Related]
3. Loss of stimulatory effect of guanosine triphosphate on [(35)S]GTPgammaS binding correlates with Alzheimer's disease neurofibrillary pathology in entorhinal cortex and CA1 hippocampal subfield.
García-Jiménez A; Cowburn RF; Ohm TG; Lasn H; Winblad B; Bogdanovic N; Fastbom J
J Neurosci Res; 2002 Feb; 67(3):388-98. PubMed ID: 11813244
[TBL] [Abstract][Full Text] [Related]
4. Loss of inositol 1,4,5-trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology.
Kurumatani T; Fastbom J; Bonkale WL; Bogdanovic N; Winblad B; Ohm TG; Cowburn RF
Brain Res; 1998 Jun; 796(1-2):209-21. PubMed ID: 9689471
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of [3H]forskolin binding by Gpp[NH]p may reflect adenylyl cyclase coupling to Gi.
García-Jiménez A; Cowburn RF; Einblad B; Fastbom J
Neuroreport; 1998 Oct; 9(14):3329-33. PubMed ID: 9831472
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of [3H]forskolin binding by Gpp[NH]p may reflect adenylate cyclase coupling to Gi.
Garcia-Jiménez A; Cowburn RF; Winblad B; Fastbom J
Neuroreport; 1999 Aug; 10(11):2423-7. PubMed ID: 10439475
[TBL] [Abstract][Full Text] [Related]
7. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies.
Kelliher M; Fastbom J; Cowburn RF; Bonkale W; Ohm TG; Ravid R; Sorrentino V; O'Neill C
Neuroscience; 1999; 92(2):499-513. PubMed ID: 10408600
[TBL] [Abstract][Full Text] [Related]
8. G-protein alpha-subunit levels in hippocampus and entorhinal cortex of brains staged for Alzheimer's disease neurofibrillary and amyloid pathologies.
García-Jiménez A; Fastbom J; Ohm TG; Cowburn RF
Neuroreport; 2003 Aug; 14(11):1523-7. PubMed ID: 12960778
[TBL] [Abstract][Full Text] [Related]
9. Adenylyl cyclase activity in Alzheimer's disease brain: stimulatory and inhibitory signal transduction pathways are differently affected.
Schnecko A; Witte K; Bohl J; Ohm T; Lemmer B
Brain Res; 1994 May; 644(2):291-6. PubMed ID: 7914148
[TBL] [Abstract][Full Text] [Related]
10. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.
Marquié M; Siao Tick Chong M; Antón-Fernández A; Verwer EE; Sáez-Calveras N; Meltzer AC; Ramanan P; Amaral AC; Gonzalez J; Normandin MD; Frosch MP; Gómez-Isla T
Acta Neuropathol; 2017 Oct; 134(4):619-628. PubMed ID: 28612291
[TBL] [Abstract][Full Text] [Related]
11. Reduced basal and stimulated (isoprenaline, Gpp(NH)p, forskolin) adenylate cyclase activity in Alzheimer's disease correlated with histopathological changes.
Ohm TG; Bohl J; Lemmer B
Brain Res; 1991 Feb; 540(1-2):229-36. PubMed ID: 2054615
[TBL] [Abstract][Full Text] [Related]
12. Forms of adenylate cyclase, activation and/or potentiation by forskolin.
Shi QH; Ruiz JA; Ho RJ
Arch Biochem Biophys; 1986 Nov; 251(1):156-65. PubMed ID: 3789730
[TBL] [Abstract][Full Text] [Related]
13. Binding of [3H]forskolin to human platelet membranes. Regulation by guanyl-5'-yl imidodiphosphate, NaF, and prostaglandins E1 and D2.
Nelson CA; Seamon KB
J Biol Chem; 1986 Oct; 261(29):13469-73. PubMed ID: 3463564
[TBL] [Abstract][Full Text] [Related]
14. Selective alterations of high affinity [3H]forskolin binding sites in Alzheimer's disease: a quantitative autoradiographic study.
Dewar D; Horsburgh K; Graham DI; Brooks DN; McCulloch J
Brain Res; 1990 Mar; 511(2):241-8. PubMed ID: 2110494
[TBL] [Abstract][Full Text] [Related]
15. Receptor-G-protein signalling in Alzheimer's disease.
Cowburn RF; O'Neill C; Bonkale WL; Ohm TG; Fastbom J
Biochem Soc Symp; 2001; (67):163-75. PubMed ID: 11447833
[TBL] [Abstract][Full Text] [Related]
16. Progression of Alzheimer-related neuritic plaque pathology in the entorhinal region, perirhinal cortex and hippocampal formation.
Yilmazer-Hanke DM; Hanke J
Dement Geriatr Cogn Disord; 1999; 10(2):70-6. PubMed ID: 10026378
[TBL] [Abstract][Full Text] [Related]
17. Brain forskolin binding in mice dependent on and tolerant to ethanol.
Valverius P; Hoffman PL; Tabakoff B
Brain Res; 1989 Nov; 503(1):38-43. PubMed ID: 2611657
[TBL] [Abstract][Full Text] [Related]
18. [3H]forskolin binding to cardiac adenylate cyclase in guinea pigs chronically infused with isoproterenol.
McMartin L; Summers RJ
Life Sci; 1995; 57(11):1039-49. PubMed ID: 7658911
[TBL] [Abstract][Full Text] [Related]
19. Effects of post-mortem delay on high affinity forskolin binding sites and adenylate cyclase activity in rat and human striatum and cerebral cortex.
Ross B; Dawson D; Dewar D; Macrae M; Knowler J; McCulloch J
Brain Res; 1993 Dec; 629(2):225-30. PubMed ID: 8111626
[TBL] [Abstract][Full Text] [Related]
20. Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology.
Thal DR; Arendt T; Waldmann G; Holzer M; Zedlick D; Rüb U; Schober R
Neurobiol Aging; 1998; 19(6):517-25. PubMed ID: 10192210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
